BioMedNewsBreaks Archive - Page 40 of 246

WednesdayMar 05, 2025 9:39 am

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters $10 Million Standby Equity Purchase Agreement

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on inflammation and immunology biological products and contract development and manufacturing organization (CDMO) services, has entered into a standby equity purchase agreement with YA II PN, Ltd., a fund managed by Yorkville Advisors Global. The agreement allows Scinai to sell up to $10 million of its American Depository Shares to Yorkville over a three-year period, subject to certain conditions, including a 9.99% beneficial ownership cap. The company retains full control over the timing and amount of any sales, with no obligations or penalties for non-use. Proceeds will support the development of Scinai's NanoAbs…

FridayFeb 28, 2025 10:45 am

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) and OS Therapies (NYSE American: OSTX) to Appear on RedChip’s Bloomberg TV Show

Calidi Biotherapeutics (NYSE American: CLDI) and OS Therapies Inc. (NYSE American: OSTX) will be featured on RedChip’s Small Stocks, Big Money™ show, airing on Bloomberg TV this Saturday, March 1, at 7 p.m. ET. Andrew Jackson, CFO of Calidi, will discuss the company’s stem cell-based oncolytic virotherapy platform designed to enhance cancer treatment. Calidi’s lead candidates, CLD-101 and CLD-201, target significant market opportunities estimated between $13 billion and $15 billion in the U.S. OS Therapies CEO Paul Romness will highlight OST-HER2, an immunotherapy targeting HER2-positive osteosarcoma and solid tumors, with potential for accelerated FDA approval. The company also advances a…

ThursdayFeb 27, 2025 3:26 pm

BioMedNewsBreaks — Adageis Tackling Healthcare’s Value-Based Shift with AI-Driven Insights, Seamless Integration

Adageis, a forward-thinking healthcare technology company, is bringing AI-driven solutions that help providers harness data to improve care efficiency and financial performance amid an industry shift from fee-for-service models to value-based care. “A major hurdle in value-based care is identifying high-risk patients before they require costly interventions. Adageis addresses this with its Patented Risk Engine (‘PRE’), which analyzes clinical and demographic data to flag individuals most likely to develop chronic conditions or experience hospital readmissions. By surfacing these insights in real time, providers can intervene earlier, reducing avoidable emergency visits and improving long-term health outcomes,” reads a recent article. “Another…

ThursdayFeb 27, 2025 10:55 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO and CFO to Present at Investor Summit Virtual on March 11

Clene (NASDAQ: CLNN) announced that CEO Rob Etherington and CFO Morgan Brown will present at the Investor Summit Virtual on March 11, 2025. The event will provide investors with insights into the company’s latest developments and strategic outlook. To view the full press release, visit https://ibn.fm/NzQFl About Clene Inc. Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system…

ThursdayFeb 27, 2025 9:58 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) to Report Q4 and Full-Year 2024 Results on March 13

HeartBeam (NASDAQ: BEAT) announced it will release its fourth quarter and full-year 2024 financial results on March 13, 2025, and host a conference call at 4:30 p.m. ET. The call will include updates on regulatory initiatives, commercial-readiness efforts, and key milestones. CEO Robert Eno and CFO Timothy Cruickshank will lead the discussion, followed by a Q&A session. A corresponding presentation will be available via the company’s investor relations website. To view the full press release, visit https://ibn.fm/nxla9 About HeartBeam Inc. HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is.…

WednesdayFeb 26, 2025 11:30 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Updates Cash Position, Nasdaq Compliance, and Clinical Progress

CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company focused on treatments for brain and central nervous system cancers, provided an update on its cash position and efforts to maintain its Nasdaq listing. The company reported a strengthened financial position, with $14 million in cash as of Feb. 26, 2025, expected to fund operations into the first quarter of 2026. CNS remains on track to announce primary data analysis for its global Berubicin trial in the first half of 2025 and plans to begin its TPI 287 clinical program by enrolling its first patient before year-end. To maintain compliance with Nasdaq’s listing…

WednesdayFeb 26, 2025 9:27 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Underwriter Exercises Option, Increasing Gross Proceeds to $11.5M

HeartBeam (NASDAQ: BEAT), a medical technology company focused on advancing cardiac care, announced that the underwriter of its recent public offering exercised its option to purchase an additional 864,033 shares at $1.70 per share. This move increases the total gross proceeds from the offering to approximately $11.5 million, before deductions. The exercise of the over-allotment option closed Feb. 25, 2025, following the initial 5,882,353 share offering that closed Feb. 14, 2025. The funds will support HeartBeam’s strategic growth initiatives, including U.S. commercialization efforts, R&D, and regulatory projects. MDB Capital served as the underwriter, with Paulson Investment Company LLC acting as…

TuesdayFeb 25, 2025 9:30 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Partners with APST Research to Advance ALS Drug Approval Process

Clene (NASDAQ: CLNN) has entered into an agreement with Germany-based APST Research GmbH to utilize its extensive neurofilament light chain (NfL) database in FDA-recommended analyses of CNM-Au8® for treating amyotrophic lateral sclerosis (ALS). APST's repository includes biomarker data from over 4,300 ALS patients, which will help Clene compare NfL changes in NIH-sponsored Expanded Access Protocol participants to matched controls. The results could support Clene’s planned New Drug Application submission for CNM-Au8 under the FDA's Accelerated Approval pathway in the second half of 2025. CEO Rob Etherington emphasized the importance of leveraging real-world evidence to advance potential treatments for ALS. To view…

MondayFeb 24, 2025 9:23 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Launches “CLD-101” Trial for High-Grade Glioma at Northwestern

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted antitumor virotherapies, said Northwestern University/Northwestern Memorial Hospital is recruiting for its Phase 1B/2 clinical trial of "CLD-101" in newly diagnosed high-grade glioma patients. The company completed shipment of the first batch of CLD-101—comprising allogeneic neural stem cells loaded with the oncolytic adenovirus CRAd-S-pk7—to support the trial, which builds on promising Phase 1 results in 12 patients published in The Lancet Oncology. The physician-led and NCI-sponsored study, headed by Dr Maciej Lesniak and Dr Roger Stupp and funded by the NIH/NCI SPORE, aims to evaluate a multiple-dose regimen that could…

FridayFeb 21, 2025 8:30 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at European Life Sciences CEO Forum

CNS Pharmaceuticals (NASDAQ: CNSP) announced that CEO John Climaco will present at the 18th Annual European Life Sciences CEO Forum in Zurich on Feb. 26, 2025, at 3:20 p.m. CET / 9:20 a.m. EST; management will also be available for one-on-one meetings with registered investors, and a video webcast of the presentation will be accessible on-demand through the conference presenters portal. To view the full press release, visit https://ibn.fm/yGKfB About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters $10 Million Standby Equity Purchase Agreement

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) and OS Therapies (NYSE American: OSTX) to Appear on RedChip’s Bloomberg TV Show

BioMedNewsBreaks — Adageis Tackling Healthcare’s Value-Based Shift with AI-Driven Insights, Seamless Integration

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO and CFO to Present at Investor Summit Virtual on March 11

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) to Report Q4 and Full-Year 2024 Results on March 13

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Updates Cash Position, Nasdaq Compliance, and Clinical Progress

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Underwriter Exercises Option, Increasing Gross Proceeds to $11.5M

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Partners with APST Research to Advance ALS Drug Approval Process

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Launches “CLD-101” Trial for High-Grade Glioma at Northwestern

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at European Life Sciences CEO Forum

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search